Fed's Bostic: Rate cut by year-end may be appropriate

Biopharmaceutical company Bioxytran, Inc. recently announced positive progress in the dose optimization study of its investigational drug Prolectin-M.

Niagen Bioscience (stock code: NAGE) recently announced its financial results for fiscal year 2025, delivering an impressive performance.

Biotechnology company PepGen Inc. recently reaffirmed its clinical development timeline, clearly stating that it will release research data from the 5 mg/kg dose group in the Freedom-2 clinical trial in the first quarter of 2026.

Users of a certain exchange may experience transaction delays or system performance degradation when conducting peer-to-peer transfers on mobile devices.